argenx to Present at BofA Securities 2025 Health Care Conference
06 Maio 2025 - 2:00AM
May 6, 2025Amsterdam,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that Tim Van Hauwermeiren, Chief Executive Officer, and members of
the management team will present at the BofA Securities 2025 Health
Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.
A live webcast of the presentation may be
accessed on the Investors section of the argenx website at
argenx.com/investors. A replay of the webcast will be available on
the argenx website for approximately 30 days following the
presentation.
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx developed and is commercializing
the first approved neonatal Fc receptor (FcRn) blocker and is
evaluating its broad potential in multiple serious autoimmune
diseases while advancing several earlier stage experimental
medicines within its therapeutic franchises. For more information,
visit www.argenx.com and follow us
on LinkedIn, Instagram, Facebook,
and YouTube.
Contacts
Media:
Ben Petokbpetok@argenx.com
Investors:
Alexandra Royaroy@argenx.com
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025
